GB2535034A - Methods and systems for microbiome characterization, monitoring and treatment - Google Patents

Methods and systems for microbiome characterization, monitoring and treatment Download PDF

Info

Publication number
GB2535034A
GB2535034A GB1602937.3A GB201602937A GB2535034A GB 2535034 A GB2535034 A GB 2535034A GB 201602937 A GB201602937 A GB 201602937A GB 2535034 A GB2535034 A GB 2535034A
Authority
GB
United Kingdom
Prior art keywords
methods
systems
treatment
monitoring
microbiome characterization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1602937.3A
Other languages
English (en)
Other versions
GB201602937D0 (en
Inventor
Cutcliffe Collen
S Eid John
H Bullard James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pendulum Therapeutics Inc
Original Assignee
Whole Biome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whole Biome Inc filed Critical Whole Biome Inc
Publication of GB201602937D0 publication Critical patent/GB201602937D0/en
Publication of GB2535034A publication Critical patent/GB2535034A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1602937.3A 2013-07-21 2014-07-21 Methods and systems for microbiome characterization, monitoring and treatment Withdrawn GB2535034A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856711P 2013-07-21 2013-07-21
PCT/US2014/047491 WO2015013214A2 (en) 2013-07-21 2014-07-21 Methods and systems for microbiome characterization, monitoring and treatment

Publications (2)

Publication Number Publication Date
GB201602937D0 GB201602937D0 (en) 2016-04-06
GB2535034A true GB2535034A (en) 2016-08-10

Family

ID=52393950

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1602937.3A Withdrawn GB2535034A (en) 2013-07-21 2014-07-21 Methods and systems for microbiome characterization, monitoring and treatment

Country Status (5)

Country Link
US (2) US10633714B2 (enExample)
JP (2) JP6637885B2 (enExample)
CN (1) CN105407728A (enExample)
GB (1) GB2535034A (enExample)
WO (1) WO2015013214A2 (enExample)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
AU2014281553A1 (en) 2013-06-18 2016-01-28 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
CN107075588B (zh) 2014-10-21 2023-03-21 普梭梅根公司 用于微生物组来源的诊断和治疗的方法及系统
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
KR101746635B1 (ko) * 2014-12-08 2017-06-13 재단법인 아산사회복지재단 박테로이데스 에시디페시언스를 유효성분으로 포함하는, 대사성 질환 예방 또는 치료용 약학적 조성물
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
WO2016168354A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
EP3283084B1 (en) * 2015-04-13 2025-08-06 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN108283012B (zh) * 2015-04-13 2021-11-23 普梭梅根公司 用于自身免疫系统状况的微生物组来源的诊断和治疗的方法及系统
WO2016168316A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
CN107708716B (zh) * 2015-04-13 2022-12-06 普梭梅根公司 用于微生物组分类学特征相关的状况的微生物组来源的诊断和治疗的方法及系统
AU2016250096A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
AU2016248120A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
AU2016250152A1 (en) * 2015-04-14 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
AU2016248115A1 (en) * 2015-04-14 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics, and therapeutics for cardiovascular disease conditions
US10788452B2 (en) 2015-04-21 2020-09-29 General Automation Lab Technologies Inc. High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT202200174T1 (it) * 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
US11001900B2 (en) 2015-06-30 2021-05-11 Psomagen, Inc. Method and system for characterization for female reproductive system-related conditions associated with microorganisms
JP6046849B1 (ja) * 2015-07-21 2016-12-21 ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
WO2017044900A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues
CN108350510B (zh) * 2015-09-09 2022-06-03 普梭梅根公司 用于胃肠健康相关病症的源自微生物群系的诊断及治疗方法和系统
WO2017044902A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for oral health
MX379207B (es) 2015-09-15 2025-03-10 Neogen Corp Métodos de detección de listeria a partir de una muestra ambiental.
EP4345725A3 (en) 2015-09-17 2024-06-19 Prodermiq, Inc. Predicting skin age based on the analysis of skin flora and lifestyle data
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3386592A4 (en) * 2015-12-09 2019-05-22 Ubiome, Inc. METHOD AND SYSTEM FOR CHARACTERIZATION WITH CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP3394289B1 (en) * 2015-12-22 2025-03-26 Vib Vzw Microbial marker in spondyloarthritis diseases
WO2017141169A1 (en) * 2016-02-16 2017-08-24 Tata Consultancy Services Limited Method and system for early risk assessment of preterm delivery outcome
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2017156031A1 (en) * 2016-03-07 2017-09-14 uBiome, Inc. Method and system for characterizing mouth-associated conditions
US10894990B2 (en) 2016-05-17 2021-01-19 Shoreline Biome, Llc High throughput method for identification and sequencing of unknown microbial and eukaryotic genomes from complex mixtures
CN109642904A (zh) 2016-05-23 2019-04-16 加州理工学院 调节肠微生物群来治疗神经退行性病症
CN107541544A (zh) * 2016-06-27 2018-01-05 卡尤迪生物科技（北京）有限公司 用于确定微生物分布谱的方法、系统、试剂盒、用途和组合物
WO2018013865A1 (en) * 2016-07-13 2018-01-18 uBiome, Inc. Method and system for microbial pharmacogenomics
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
EP3511406A4 (en) * 2016-09-06 2020-04-01 BGI Shenzhen FAECALIBACTERIUM LONGUM AND APPLICATION THEREOF
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
CA3036994A1 (en) * 2016-09-16 2018-03-22 uBiome, Inc. Method and system for panel characterizations
CA3038661C (en) * 2016-09-27 2025-05-06 Psomagen, Inc. METHOD AND SYSTEM FOR PREPARING AND SEQUENCING CRISPR-BASED BANK
WO2018064385A1 (en) * 2016-09-28 2018-04-05 General Automation Lab Technologies, Inc. High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications
US11015154B2 (en) 2016-11-09 2021-05-25 The Regents Of The University Of California Methods for identifying interactions amongst microorganisms
JP6955860B2 (ja) * 2016-11-30 2021-10-27 花王株式会社 デリケートエリアのかぶれ判定方法
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3775257A4 (en) * 2016-12-15 2022-03-09 Psomagen, Inc. METHOD AND SYSTEM FOR CHARACTERIZING ALLERGY RELATED CONDITIONS ASSOCIATED WITH MICROORGANISMS
EP3776285A4 (en) * 2016-12-16 2022-03-09 Psomagen, Inc. METHOD AND SYSTEM FOR CHARACTERIZING MICRO-ORGANISM-RELATED CONDITIONS
US20200056225A1 (en) * 2017-02-24 2020-02-20 Md Healthcare Inc. Method for diagnosing chronic obstructive airway disease through bacterial metagenome analysis
EP3593267A4 (en) * 2017-03-10 2020-12-30 Prodermiq, Inc. SKIN CARE PRODUCTS AND PERSONAL CARE PRODUCTS CUSTOMIZED BY SKIN FLORA ANALYSIS
CN107034279A (zh) * 2017-05-05 2017-08-11 中山大学 结核病微生物标志物在制备诊断结核病的试剂中的应用
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
CN109082479B (zh) * 2017-06-14 2022-04-19 深圳华大生命科学研究院 从样本中鉴定微生物物种的方法和装置
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020532979A (ja) * 2017-08-28 2020-11-19 プソマーゲン， インコーポレイテッドＰｓｏｍａｇｅｎ， Ｉｎｃ． 微生物に関連する女性生殖器系関連状態の特徴解析のための方法及びシステム
EP3677272B1 (en) * 2017-08-29 2022-11-16 BGI Shenzhen Application of alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
KR101831416B1 (ko) * 2017-09-04 2018-02-22 이화여자대학교 산학협력단 시료 내 미생물 군집의 변화를 이용한 조산 위험성 예측
CN111315898A (zh) * 2017-11-06 2020-06-19 普梭梅根公司 用于微生物相关表征过程的控制过程
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019125299A1 (en) * 2017-12-22 2019-06-27 Gutfeeling Labs Ab Method for analysis of health status
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
WO2019151825A1 (ko) * 2018-02-02 2019-08-08 주식회사 엠디헬스케어 비피도박테리움 속 세균 유래 나노소포 및 이의 용도
KR102194286B1 (ko) 2018-02-08 2020-12-22 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
WO2019156449A1 (ko) * 2018-02-08 2019-08-15 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
KR102118989B1 (ko) * 2018-03-05 2020-06-05 주식회사 엠디헬스케어 엔히드로박터 세균 유래 나노소포 및 이의 용도
US11525164B2 (en) 2018-03-27 2022-12-13 The Trustees Of Columbia University In The City Of New York Spatial metagenomic characterization of microbial biogeography
KR101872457B1 (ko) * 2018-04-20 2018-06-28 이화여자대학교 산학협력단 혈액 내 미생물 군집의 변화를 이용한 조산 위험성의 예측
WO2020004626A1 (ja) * 2018-06-29 2020-01-02 国立大学法人大阪大学 眼表面組織を用いる結膜疾患検出方法及び老化バイオマーカー
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3113524A1 (en) * 2018-09-19 2020-03-26 Tor Savidge Precision diagnosis of clostridioides difficile infection using systems-based biomarkers
CN109273046B (zh) * 2018-10-19 2022-04-22 江苏东南证据科学研究院有限公司 一种基于概率统计模型的生物学全同胞鉴定方法
SG11202104224SA (en) * 2018-10-26 2021-05-28 Sun Genomics Inc Universal method for extracting nucleic acid molecules from a diverse population of microbes
CN113348367A (zh) * 2018-10-31 2021-09-03 卡尤迪医学检验实验室（北京）有限公司 用于预测早产状况的方法、系统和试剂盒
WO2020093040A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Methods to diagnose and treat cancer using non-human nucleic acids
WO2020213732A1 (ja) * 2019-04-18 2020-10-22 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
WO2021044415A1 (en) * 2019-09-02 2021-03-11 My-Or Diagnostics Ltd. Skin microbiome monitoring for improving systemic health
BR112022006282A8 (pt) * 2019-10-04 2023-03-21 Vytelle Llc Composições, métodos e kits para seleção de doadores e receptores para fertilização in vitro
CN110903999B (zh) * 2019-10-23 2021-11-23 上海市第十人民医院 一株人类肠道分离的具核梭杆菌动物亚种菌株及其应用
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
WO2021156718A2 (en) * 2020-01-29 2021-08-12 Tata Consultancy Services Limited Method and composition for microbiome based amelioration of skin associated autoimmune inflammatory diseases
US20210265029A1 (en) * 2020-02-21 2021-08-26 Zoe Global Limited Generating microbiome fingerprints, dietary fingerprints, and microbiome ancestry
WO2021202584A1 (en) * 2020-03-30 2021-10-07 The Regents Of The University Of California Systems and methods for gut microbiome precision medicine
US20210319848A1 (en) * 2020-04-08 2021-10-14 Fred Hutchinson Cancer Research Center Systems and methods for identifying associations between microbial strains and phenotypic features
CN114078568B (zh) * 2020-09-14 2022-07-05 青岛欧易生物科技有限公司 基于iib型限制性内切酶特征的宏基因组测序数据处理系统及处理方法
US11139063B1 (en) 2020-12-29 2021-10-05 Kpn Innovations, Llc. Systems and methods for generating a microbiome balance plan for prevention of bacterial infection
US12322493B2 (en) * 2020-12-29 2025-06-03 Kpn Innovations, Llc. Systems and methods for generating a lifestyle-based disease prevention plan
US12322491B2 (en) 2021-03-01 2025-06-03 Kpn Innovations, Llc. System and method for generating a geographically linked nourishment program
KR102304402B1 (ko) * 2021-03-26 2021-09-24 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 비만 여부를 판별하는 방법 및 진단 장치
JP7643909B2 (ja) * 2021-03-30 2025-03-11 株式会社日立ハイテク 分析装置、分析システム、分析方法、およびプログラム
CN112961807B (zh) * 2021-03-30 2023-01-20 中国科学院成都生物研究所 一种微生物组合物及在促进青稞种子发芽和生长上的应用
WO2022211796A1 (en) * 2021-03-31 2022-10-06 Neogen Corporation Detecting salmonella from an environmental sample
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CN114807392B (zh) * 2021-12-08 2025-02-25 杭州拓宏生物科技有限公司 精神分裂症标志微生物及其应用
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
CN114373505B (zh) * 2021-12-29 2022-11-01 浙江大学 一种基于肠道微生物早期预测奶牛产后亚临床酮病的系统
KR102760485B1 (ko) * 2022-01-03 2025-02-03 연세대학교 산학협력단 자궁내막증 진단을 위한 정보 제공 방법
US20230268041A1 (en) * 2022-02-23 2023-08-24 Jona, Inc. System and method for using the microbiome to improve healthcare
US20250349433A1 (en) * 2022-05-11 2025-11-13 J. Craig Venter Institute, Inc. Methods and systems for determining dental caries
JP7748113B2 (ja) * 2022-12-14 2025-10-02 イムノバイオーム インコーポレイテッド マシンラーニングモデルを使用して特定の疾病に関連する微生物群集データを導出する方法
CN115980346B (zh) * 2022-12-26 2025-07-15 云南大学 一种基于金属有机框架材料构建比色免疫传感器检测新型冠状病毒的方法
WO2024200517A1 (en) * 2023-03-28 2024-10-03 Zoe Limited Microbiome and dietary fingerprints, and methods including directional alteration of microbiome composition
CN117965384B (zh) * 2024-02-08 2025-11-21 北京林业大学 一种用于液化降解餐厨垃圾的降解菌及包含其的菌剂和应用
CN118813503B (zh) * 2024-09-19 2025-05-27 中国海洋大学 一种索氏鲸杆菌、索氏鲸杆菌后生元及其制备方法和应用
CN119614730B (zh) * 2025-02-17 2025-05-13 美益添生物医药(武汉)有限公司 一种与帕金森综合征相关的肠道菌群标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
CA2153391C (en) 1993-01-11 2000-08-15 Kenneth Rock Inducing cytotoxic t lymphocyte responses
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP5565991B2 (ja) 2004-12-15 2014-08-06 株式会社島津製作所 微生物菌種推定システム及び方法
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2008117266A2 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
CA2682327A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium strains
EP1985712A1 (en) * 2007-04-17 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Microbial population analysis
US8478544B2 (en) * 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
DK3181134T3 (da) 2009-06-19 2020-01-20 Dupont Nutrition Biosci Aps Bifidobakterier til behandling af diabetes og relaterede tilstande
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
BR112012001812B1 (pt) 2009-07-30 2019-04-16 Dupont Nutrition Biosciences Aps Uso de bactéria para o tratamento da endotoxemiametabólica em mamífero
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
CN101792807B (zh) * 2010-03-25 2012-12-05 复旦大学 一种微生物群落结构的分析方法
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
EP2753187B2 (en) 2011-08-30 2025-08-06 Caelus Pharmaceuticals B.V. Method for preventing and/or treating insulin resistance
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2013142378A1 (en) 2012-03-17 2013-09-26 The Regents Of The University Of California Fast diagnosis and personalized treatments for acne
KR20210013352A (ko) 2012-09-20 2021-02-03 프로테라 인코포레이티드 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
PL3628161T3 (pl) 2012-11-23 2023-08-07 Seres Therapeutics, Inc. Synergistyczne kompozycje bakteryjne i sposoby ich wytwarzania oraz stosowanie
HK1219022A1 (zh) 2013-02-04 2017-03-24 Seres Therapeutics, Inc. 填充胃肠道的方法
EP3904502A3 (en) 2013-02-04 2022-02-23 Seres Therapeutics, Inc. Compositions and methods
US20160000838A1 (en) 2013-03-05 2016-01-07 Rijksuniversiteit Groningen Use of Faecalibacterium Prausnitzii Htf-f (DSM 26943) to Suppress Inflammation
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319525D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US20150246081A1 (en) 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
FI127483B (en) 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOWMAN et al. Analysis of Full-Length Metagenomic 16S Genes by SMRT Sequencing. American Society for Microbiology 2013 General Meeting 19 May 2013 Poster Session pg 116 Poster 390. Available on the Internet:< http://www.asm.org/index.php/asm-events/post-meeting¬materials *
EID et at. Real-time DNA sequencing from single polymerase molecules. Science 2 January 2009 Vol 323 No 5910 Pages 133-138. Especially pg 134 col 3 para 4, pg 136 fig 3B. *

Also Published As

Publication number Publication date
WO2015013214A2 (en) 2015-01-29
CN105407728A (zh) 2016-03-16
JP2016525355A (ja) 2016-08-25
WO2015013214A3 (en) 2015-03-26
JP6637885B2 (ja) 2020-01-29
US20150259728A1 (en) 2015-09-17
GB201602937D0 (en) 2016-04-06
US20200277658A1 (en) 2020-09-03
US10633714B2 (en) 2020-04-28
JP2020072680A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
MX2015012733A (es) Metodos y composiciones para evaluar el estado renal usando adn libre de celulas de la orina.
IL252361A0 (en) Preparations and methods for the treatment and diagnosis of cancers resistant to chemotherapy
MY166062A (en) St2l antagonists and methods of use
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
ZA201600453B (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
MX381640B (es) Metodos y compuestos agonistas de gip.
EP3003139C0 (en) MODULAR PHYSIOLOGICAL MONITORING SYSTEMS, KITS AND METHODS
EP2986140A4 (en) COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
LT2890717T (lt) Diagnostiniai tyrimai ir rinkiniai, skirti foliato receptoriaus 1 nustatymui
MX2014009143A (es) Metodos y sistemas para evaluar la actividad muscular electrica en respuesta a la estimulacion de un nervio motor.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
DK3065764T6 (da) Mini-gastrin-analog, især til anvendelse i CCK-2-receptor-positive tumordiagnoser og/eller -behandling
FI3511422T3 (fi) Menetelmiä ja koostumuksia endometriooosin diagnosointia, ennustamista ja hoitoa varten
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
PH12015501627B1 (en) Kv1.3 antagonists and methods of use
IN2015DN01524A (enExample)
BR112016008975A2 (pt) Métodos para detectar, monitorar o desenvolvimento e avaliar a eficácia de um tratamento de uma doença autoimune
MA40406A (fr) Procédés et compositions de diagnostic et de traitement des maladies inflammatoires chroniques de l&#39;intestin
EP3016587A4 (en) Device and methods for assessing, diagnosing, and/or monitoring heart health
MX377276B (es) Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda).
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
EP2866565A4 (en) METHOD FOR TREATING, DIAGNOSIS AND / OR MONITORING THE PROGRESSION OF OXO ASSOCIATED STATES

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)